Home>Topics>Stocks>Holly Energy Partners

Holly Energy Partners HEP

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Headlines
    1. If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits

      Headlines

      Tue, 16 Sep 2014

      By Adam Gefvert, CFA : Achillion Pharmaceuticals (NASDAQ: ACHN ) is a biotech company that focuses on developing treatments for Hepatitis C (HCV). Most of the company's value is riding on the success of its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only

    2. Gilead licenses Sovaldi to Indian firms

      Headlines

      Mon, 15 Sep 2014

      developing countries representing more than 100M people infected with hep C (54% of the global infected population). The Indian companies ..... manufacture of sofosbuvir or ledipasvir in combination with other chronic hep C medicines. Post your comment!

    3. BRIEF-Gilead Sciences says licensed Hep C drug sovaldi to 7 companies

      Headlines

      Mon, 15 Sep 2014

      * Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories, Ranbaxy

    4. Profit taking pushes Achillion down in early trading

      Headlines

      Fri, 5 Sep 2014

      the party on June 10 when it announced the lifting of the clinical hold on its hep C candidate sovaprevir imposed by the FDA and the initiation of patient dosing in a Phase 1 trial of ACH-3422 in hep C genotype 1 patients. Post your comment!

    5. Immunotech completes field trials on HIV/ Hep C treatment in Bulgaria

      Headlines

      Thu, 28 Aug 2014

      Immunotech Laboratories ( OTCPK:IMMB -16.7% ) completes Phase 1 and Phase 2 trials of its HIV/AIDS and Hepatitis C virus treatment ( ITV-1 ) in Bulgaria. It has also completed toxicity testing and pharmacokinetic analyses on animals. The firm is preparing its application for a permit to proceed to

    6. UPDATE 1-Gilead says panel rejects Roche's claims on hep C drug

      Headlines

      Fri, 15 Aug 2014

      (Adds analyst comment, background; updates share movement)

    7. Gilead says wins favorable ruling on hep C drug

      Headlines

      Fri, 15 Aug 2014

      Aug 15 (Reuters) - Gilead Sciences Inc said an arbitration panel has ruled in its favor, rejecting patent infringement claims from Roche Holding AG, related to Gilead's hepatitis C drug, Sovaldi.

    8. Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential

      Headlines

      Tue, 12 Aug 2014

      ARC-520 is being studied as a functional cure for hepatitis B ( Hep B). The compound showed great promise in pre-clinical proof ..... a Phase 2a efficacy and escalating dosing study with chronic Hep B patients in March of 2014 and completed earlier this summer

    9. Holly Energy Raises Distribution Despite Lower Pipeline Volumes in Second Quarter

      Commentary

      Wed, 6 Aug 2014

      Holly Energy Partners reported second-quarter results on Aug. 5 that fell short of expectations, primarily due to decreased throughput volumes on

    10. New Morningstar Analyst Report for HollyFrontier Corp

      Stock Reports

      Wed, 6 Aug 2014

      board and chairman and CEO of Holly Energy Partners L.P. Mike Jennings, CEO ..... has a 39% ownership stake in Holly Energy Partners , which owns and operates petroleum ..... the value in the ownership of HEP . Our fair value estimate implies

    « Prev12345Next »
    Content Partners